Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
| ▸ | AKT2 | P31751 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | TEK | Q02763 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23649477 | 0.98 | AKT1 (0.57) | AKT1AKT2IDO1METAP2KDR | |
| SCHEMBL16727395 | 0.87 | IDO1 (0.51) | AKT1AKT2IDO1METAP2KDR | |
| SCHEMBL30424015 | 0.86 | AKT2 (0.71) | AKT1AKT2PIM1PIM3PIM2 | |
| SCHEMBL27476106 | 0.79 | KCNH2 (0.52) | AKT1AKT2KDRTEKPIM1 | |
| SCHEMBL25272757 | 0.78 | AKT1 (0.55) | AKT1AKT2ROCK2 | |
| SCHEMBL30456033 | 0.78 | AKT1 (0.55) | AKT1AKT2ROCK2 | |
| SCHEMBL28182653 | 0.77 | KCNH2 (0.54) | AKT1AKT2KDRTEKPIM1 | |
| SCHEMBL980068 | 0.77 | CHEK1 (0.59) | AKT1AKT2METAP2ROCK2LMNA | |
| SCHEMBL23804742 | 0.77 | AKT2 (0.59) | AKT1AKT2IDO1ROCK2 | |
| SCHEMBL22861241 | 0.77 | AKT2 (0.59) | AKT1AKT2IDO1PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486274-B2 | Substituted pyrazolo-pyrimidines and uses thereof | Verge Analytics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| CN-115209952-B | Substituted pyrazolopyrimidines and use thereof | 维基分析有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4444316-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| WO-2023107592-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107557-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067537-A1 | PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007056023-A2 | THIAZOLE INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-0388659-A1 | Azole-1-alkanamides as antiarrhythmic agents and preparation thereof | STERLING DRUG INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4888352-A | 3,4, or 5-aryl-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use | STERLING DRUG INC. (US) | 1989-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | PIKFYVE, TARDBP, TDP1 | AKT1 909/4885AKT2 1149/4885IDO1 4471/4885 |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | AKT1 36/4885AKT2 94/4885IDO1 4469/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | AKT1 2233/4885AKT2 2392/4885IDO1 1745/4885 |
| US-12486274-B2 | Substituted pyrazolo-pyrimidines and uses thereof | PIKFYVE, PIP4K2B, PIP4K2C | AKT1 250/4885AKT2 207/4885IDO1 4336/4885 |
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | PIKFYVE, PIK3CA, PIK3CB | AKT1 100/4885AKT2 91/4885IDO1 3254/4885 |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | JAK2, ABL1, FLT3 | AKT1 374/4885AKT2 533/4885IDO1 3966/4885 |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | AKT1 151/4885AKT2 111/4885IDO1 1153/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | AKT1 191/4885AKT2 443/4885IDO1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.